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BACKGROUND: Cerebrospinal fluid (CSF) leakage is one of the most common neurosur-
gical complications, occurring in 4% to 32% of surgical cases, with a higher incidence in
complicated skull base surgery, intradural spine surgery, and the surgery of the posterior
fossa. Our group developed a Dural Sealant Patch (DSP) for watertight dural closure after
cranial surgery.
OBJECTIVE: To clinically study for the first time the safety and performance of the DSP as a
means of reducing CSF leakage in patients undergoing elective cranial intradural surgery
with a dural closure procedure.
METHODS: We will conduct an open-label, single-arm, multicenter study with a 360 d
(12 mo) follow-up. A total of 40 patients will be enrolled at 3 sites. The primary endpoint is
a combination of occurrences of one of the following events: postoperative percutaneous
CSF leakage, intraoperative leakage at 20 cm H2O, or postoperative wound infection. The
secondary endpoints are pseudomeningocele and thickness of dura+ DSP.
EXPECTED OUTCOMES: Not more than 3 patients will meet the primary endpoint
suggesting safety and efficacy.
DISCUSSION:Asanext step, a randomizedcontrolled trial against thebest currentpractice
will follow to evaluate if DSP reduces CSF leakage while its safety is noninferior.
KEYWORDS: Dura, Sealing, CSF, Leakage, Prevention
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RATIONALE AND BACKGROUND INFORMATION
Cerebrospinal fluid (CSF) leakage is one of the most common
neurosurgical complications, occurring in 4% to 32% of surgical
cases, with a higher incidence in complicated skull base surgery,
intradural spine surgery, and the surgery of the posterior
fossa.1,2 Most patients with CSF leakage necessitate a prolonged
hospital stay, antibiotic treatment for meningitis, external lumbar
drainage, reoperation, or a combination of these measures. CSF
leakage leads to a significant patient burden and expense, with
an estimated cost of 10 000 to 15 000 US dollars per patient
per leakage.2 The use of a dural sealant as an adjunct to primary
dural closure is often assumed to prevent further CSF leakage.
However, until now no sealant has shown to have a significant
reducing effect.3
The sponsor of this study (Polyganics BV, Groningen, The
Netherlands) has developed in close cooperation with the Brain
Technology Institute (Utrecht, The Netherlands) a Dural Sealant
Patch (DSP) for watertight dural closure after cranial surgery.
Preclinical studies showed a better adherence to dura and burst
pressures for this sealant than currently used sealants. (Submitted)
biological safety hazards of DSP have been addressed. Based on
these data, DSP was considered safe for implantation. Until the
current study, DSP was not tested in human subjects.
STUDY GOALS ANDOBJECTIVES
The objective of this study is to clinically assess the safety and
performance of DSP as a means of reducing intra- as well as
postoperative CSF leakage in patients undergoing elective cranial
intradural surgery with a dural closure procedure.
Primary Endpoint
A composite endpoint of any neurosurgical event is defined as
follows.
Safety
Incidence of wound infection within 30 d defined in accor-
dance with the Centers for Disease Control and Prevention
guidelines for superficial incisional, deep incisional, and organ
space infections.
Performance
Incidence of intraoperative CSF leakage after patch application
at a positive end expiratory pressure (PEEP) of 20 cm H2O.
Incidence of percutaneous CSF leak confirmed by a β-2 trans-
ferrin test up to 30 d after surgery.
Secondary Endpoints
Safety
Incidence of device-related adverse events (AEs) throughout
the study up to 90 d after surgery.
Incidence of device-related AEs throughout the study up to
360 d after surgery.
Incidence of wound infection confirmed by an increase in C-
reactive protein (CRP) and positive cultures up to 90 d after
surgery.
Performance
Incidence of percutaneous CSF leakage confirmed by a β-2
transferrin test up to 90 d after surgery.
Incidence of pseudomeningocele with the need of puncture,
external lumbar drainage, or surgical evacuation, as assessed by
the treating physician, up to 90 d after surgery.
Incidence of pseudomeningocele >20 cc, as confirmed on
magnetic resonance imaging (MRI).
Thickness of dura mater and DSP (combined) in mm analyzed
with MRI.
Additional Endpoints
Incidence of complications requiring a reintervention up to
30 d after surgery.
Ease of use and application of the DSP (standardized question-
naire).
STUDY DESIGN
This study will be conducted as an open-label, single-arm,
multicenter study with a 360 d (12 mo) follow-up. In this study,
each subject will receive 1 DSP after the closure of the dura mater.
The dura mater will be closed with suturing. If deemed necessary
by the surgeon, a substitute (autologous tissue only) can be used.
The assessments performed in this study as well as the
timepoints are described in the study scheme (Figure 1).
Follow-up of the subjects will be performed on day 7 (or at
discharge, whichever comes first) and at 30, 90, and 360 d after
cranial surgery.
Research Population
This study is planned to enroll up to 40 subjects at 3 sites,
scheduled for elective cranial surgery. We aim to stratify and
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FIGURE 1. Study scheme.
enroll 34 supra- and 6 infratentorial trepanations. A maximum of
25 subjects will be enrolled per site.
Inclusion/Exclusion Criteria
Preoperative Inclusion Criteria
• Subjects who are able to provide a written informed consent
prior to participating in the clinical investigation.
• Subjects who are ≥18 yr old.
• Subjects who are able to comply with the follow-up or other
study requirements.
• Subjects who are planned for an elective intracranial intradural
surgery in whom a dural incision of at least 2 cm in length is
necessary, which will be closed.
• Female subjects of child-bearing potential must agree to use any
form of contraception from the time of signing the informed
consent form through 90 d postsurgery.
Preoperative Exclusion Criteria
• Female subjects who are pregnant or breastfeeding.
• Subjects with an assumed impaired coagulation due to
medication or otherwise.
• Subjects suspected of an infection requiring antibiotics.
• Subjects with any type of dural diseases in the planned dural
closure area.
• Subjects requiring reopening of the planned surgical area within
90 d after surgery.
• Subjects requiring local radiotherapy in the planned surgical
area.
• Subjects with a known allergy to any of the compo-
nents (lactide-caprolactone copolyester; butanediol-BDI
copolyurethane; polyethylene glycol succinimidyl gluterate;
disodium hydrogen phosphate or D&C Green No 6) of the
DSP.
• Subjects who previously participated in this study or any inves-
tigational drug or device study within 30 d of screening.
• Subjects with a presence of hydrocephalus.
• Subjects with a contraindication to MRI [cardiac pacemaker
or defibrillator, severe claustrophobia, injured by a metallic
object that was not removed, cochlear (ear) implants, metallic
implants (eg, knee replacement)].
Intraoperative Inclusion Criteria
Subjects will be eligible according to the following criteria:
• Surgical wound classification Class I/Clean.
• Minimally 5 mm of dural space surrounding the dural opening.
Intraoperative Exclusion Criteria
• Subjects in whom the elevation of PEEP or pCO2 has a
potential detrimental effect.
• Subjects who will require a CSF or wound drain, electrodes,
or other devices passing the dural layer or extra to intracranial
bypass surgery.
• Primary closure of the dura mater with synthetic, nonautol-
ogous or autologous material other than galea.
• A gap >3 mm after the primary closure of the dura mater.
• Dural opening cannot be covered by DSP (8 by 8 cm) with a
5-mm overlap.
Investigational Device Description
The bioresorbable DSP is indicated for use as an adjunct to
standard methods of dural closure, such as suturing, to provide a
watertight closure of the dura mater to prevent CSF leakage after
the dural closure procedure.
DSP is a flexible patch that consists of two layers: the adhesive
layer (white) and the sealing layer (blue) (Figure 2). The white
adhesive layer is foam-shaped and consists of bioresorbable
copolyester. The white foam will strongly adhere to the dura due
to the incorporated Polyethylene glycol-N-hydroxysuccinimide
(PEG-NHS) adhesive component and buffer salt. This layer reacts
with amines in the dural tissue in a moist environment, forming
covalent bonds between the device and the tissue.
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FIGURE 2. Investigational device. Length 8 cm, width 8 cm, and weight
1600 to 2000 mg.
The other side of the product, the watertight sealing layer, is
made from blue-colored bioresorbable polyurethane (PU). The
colorant is added to clearly distinguish between the sides of the
product, so the correct (white) side will be placed to the dura.
METHODOLOGY
Device Implantation
• The package with DSP is taken out of the freezer at least 10
min and maximum of 8 h before use.
• Dura mater should be closed with the standard method of
suturing.
• The dura mater surface is rinsed from particles (such as bone
dust) with a physiological saline.
• Dura mater surface should be moist (remove excessive fluid if
applicable).
• Hemostasis should be achieved.
• Open the aluminum pouch and also the inner blister (both not
sterile).
• DSP is cut into the required size.
• The white side of the dry DSP is positioned against the sutured
area of the dura mater if
◦ maximum gap between sutures is 3 mm or smaller; and
◦ minimal cover is 5 mm beyond the margins of the gaps in
the sutured area at all edges.
• A moist gauze is used to compress the DSP for 2 min.
Measurements
Preoperative
Demographic information will be collected at screening to
obtain information regarding gender, child-bearing potential, age,
length, weight, and body mass index of the patient. Also, infor-
mation will be collected about the subjects’ medical as well as
surgical history (ie, reason for surgery, allergies, tobacco use, use
of medication). Comorbidity will be collected at screening as well.
Intraoperative
Surgery indication, used device size (original or adjusted by
cutting), LOT number, location of incision, primary technique
for the closure of the dura (with or without galea), and type and
size of suture. The type of suture should be absorbable.
To determine the intraoperative CSF leakage before and after
the application of the DSP, the CSF pressure will be raised by
increasing PEEP and eventually, if needed, pCO2. The PEEP will
be increased to 20 cmH2O for 20 s. In case the level of saline/CSF
does not rise during this interval, the PEEP is returned to normal
and the end-tidal pCO2 will be increased in acceptable steps to a
maximum of 6.5% for 60 s. In case the level of saline/CSF does
not rise during this interval, this will be combined with a PEEP
increase to 20 cm H2O for 20 s.
First, this test will be performed before the closure of the
dura to determine the safety for the postoperative intracranial
field (control of hemorrhage, swelling, or other potential adverse
effects) and to determine at what point the CSF rises.
Upon completion of the primary sutured dural closure and
before the application of the DSP, the closure of the dura will
be evaluated for CSF leakage by repeating the test.
After the application of the DSP and before the closure of the
cranium, the PEEP (and if applicable the pCO2) elevation test
will be performed for the third time to evaluate CSF leakage.
A photograph will be taken before and after the device appli-
cation. This photograph will need to include the subject ID as
well as a ruler. The ruler will need to have a metric system with at
least a mm-scale. The photographs need to be uploaded into the
electronic case report form (e-CRF).
Follow-up
On day 7 or discharge (whichever comes first), day 30, day 90,
and day 360, a physical exam will be performed.
All subjects will undergo an MRI on day 7 or discharge
(whichever comes first) and on day 90. An MRI on day 30 will
only be performed if there are clinical signs of leakage or there
is a subcutaneous fluid pocket at any time point in the 30-d
postoperative period. An independent radiologist will analyze the
MRIs of all subjects for the presence of extradural CSF, volume
of extradural fluid pockets, and thickness of dura plus sealant.
If external leakage from wounds is visible, a β-2 transferrin test
will be performed.
During the hospitalization, the subject will be monitored
daily for clinical signs of infection. The surgical wound will be
inspected daily starting 24 h after surgery. Data will be collected
from 24 h after surgery and thereafter every 24 h until day
7 or discharge (whichever comes first). Blood analysis will be
performed in the case of clinical signs of infection.
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(Serious) adverse events (SAEs) will be documented directly
after the application of the investigational device till the last
follow-up contact.
After the procedure, surgeons will be invited to complete
several closed-end questions regarding their user experience with
DSP.
DISCUSSION
This is a first in human trial combining the safety and efficacy
of the DSP at one endpoint. This trial will give a first suggestion
on safety and efficacy. However, as a next step a randomized
controlled trial against the best current practice will have to follow
to evaluate if DSP significantly reduces CSF leakage while its
safety is noninferior.
TRIAL STATUS
Recruiting
Safety Considerations
Preclinical studies showed a better adherence to dura
and increased burst pressures than currently used sealants.
(Submitted) biological safety hazards of DSP have been addressed
to conform to ISO 10993 (biological evaluation of medical
devices)4 in a series of in-Vitro and/or in-Vivo studies: Cytotox-
icity, Sensitization, Irritation, Acute, Sub-Acute and Sub-Chronic
toxicity, Pyrogenicity, Hemocompatibility, Genotoxicity, Neuro-
toxicity, Local Effects and In-Vivo Degradation up to 12 months
(submitted). Based on these data, DSP was considered safe for
implantation.
DATAMANAGEMENT AND STATISTICAL
ANALYSIS
Research coordinators at the clinical site will perform primary
data collection drawn from source document (hospital records)
reviews. The e-CRF will be completed on a continuous basis
starting from the point of enrolling the subject to final follow-
up. The sponsor will provide clinical monitoring, including a
review of e-CRF with verification against the source documen-
tation. This may include worksheets retained with the e-CRF
documentation and hospital records.
Data will be collected through an electronic data capturing
(EDC) system on the e-CRF, a secure, internet-based case report
form and image transfer software. This system will be used to
record all subject information collected in the clinical investi-
gation for secure data tracking and centralized data monitoring
(“remote monitoring”).
Automated, real-time data analyses built into the database
enable complete control on study outcomes and safety assess-
ments.
The principal investigator or his/her designee at the clinical
site will perform primary data collection by entering the data
into the e-CRF, using a standard internet browser. Only the
principal investigator or other predesignated clinical investigation
site personnel will be authorized to enter data (from source
documents) via the internet-based e-CRF, using a unique user
name and password. Each user access to the system will be tracked
so that all data operations can be monitored and verified.
Monitoring
The sponsor’s designated monitor shall ensure appropriate
training is provided to all site personnel involved prior to the start
of the clinical investigation.
The principal investigators, using their personal login infor-
mation, shall approve and date each case report form section in
the EDC system.
The monitor, using his/her personal login information, shall
verify all critical data points against the source documents and
issue electronic queries for the authorized clinical site personnel
to respond.
A case report form section shall be considered complete when
all data are entered, verified by the monitor, outstanding queries
resolved, and signed off by the principal investigator.
A critical quality control shall be performed for the first
2 subjects by the sponsor’s designated data management team and
queries issued where needed.
After the monitor has done the source document verification
and obtained satisfactory answers to eventual queries from the
site, a full quality control shall be performed on the monitored
data throughout the clinical investigation by the designated data
management team and queries issued where needed. This process
will be repeated till the end of the clinical investigation so as to
allow for a timeline freezing of the database for statistical analysis.
Statistical Analysis
For the purpose of sample size calculation, the primary
outcomemeasurement is assumed to be the composite of the three
primary endpoints. Each patient will score “yes” if any of the three
occurs and “no” otherwise. This binary outcome is assumed to
follow a binomial distribution. The percentage of patients scoring
“yes”, along with an exact (Clopper-Pearson) two-sided 95% CI
for percentage, will be reported. Overall statistical success will be
concluded if the percentage of patients scoring “yes” is 7% or less.
This is based on a previously reported neurological complications
rate of 7.7%.5 As this is a single-group pilot study, the sample
size calculation is based on specifying the width of the CI around
the primary outcome measure, rather than aiming to demon-
strate noninferiority or superiority to a given complication rate. If
the percentage observed in the study were to be 7%, 35 patients
would be required for a CI with a width no more than 20%.
Allowing for 12.5% dropping out, the study will aim to recruit
40 patients.
QUALITY ASSURANCE
The study coordinator and investigators followed accredited
good clinical practice (GCP) training and the study is performed
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according to GCP regulations. A Data Safety Monitoring Board
(DSMB) will be installed. The DSMB will advise the sponsor
regarding the continuing safety of current participants and those
yet to be recruited. The DSMB will also review data relating
to safety and performance and ensure the continued scientific
validity and merit of the study. Interim safety analysis will be
performed after 10 patients.
EXPECTED OUTCOMES OF THE STUDY
Not more than 3 patients will meet the primary endpoint
suggesting safety and efficacy.
DURATIONOF THE PROJECT
Inclusion—final 12 mo follow-up: 18 mo.
PROJECTMANAGEMENT
Principal Investigator: Dr T. P. C. van Doormaal, MD, PhD
Site Coordinator Zurich: Dr M. R. Germans, MD, PhD
Site Coordinator Tilburg: Dr P. R. A. M. Depauw, MD, PhD
Project Managers Sponsor: A. Piteira Banga, MSc, and B. J.
Korteling, MSc
Clinical Research Manager Sponsor: E. Maas-Soer, MSc
ETHICS
Regulation
The study will be performed in accordance with the Medical
Device Directive (MDD 93/42/EEC and MEDDEV 2.7/3 rev.
3; 2015),6 MEDDEV 2.7/4,7 World Medical Association Decla-
ration of Helsinki,8 and ISO 14155:2011.9 The ENCASE
protocol was approved by the Medical Ethical Commission
in Utrecht, the Netherlands (NL64477.041.18), the Dutch
Inspection for Healthcare and Youth (IGJ), and the Swiss Medical
Ethical Board (BASEC 2018-0 1073).
Informed Consent
Prior to signing the Informed Consent Form (ICF), patient
information should be given in a language and fashion under-
standable to the patient. Information should be provided written
as well as oral. Patients should not be coerced, persuaded, or
unduly influenced to (continue to) participate in the study.
Patients should be given ample time (at least 24 h) and oppor-
tunity to enquire information regarding the study, ask questions
regarding their possible treatment and enrolment, and consider
their participation. All questions should be answered to the satis-
faction of the patient. Patient-informed consent must be obtained
prior to any study activities. The ICF should be signed and dated
by the patient, and the person conducting the informed-consent
discussion. In case the patient is unable to read and understand
the ICF, a witness should be present during the entire informed-
consent discussion. This witness should also sign the ICF, stating
that informed consent was freely given by the patient. The patient
should receive one of the 2 signed and dated copies of the ICF.
Disclosures
This study is funded by Polyganics BV, Rozenburglaan 15A, 9727 DL
Groningen, The Netherlands. Dr van Doormaal received a consultancy fee in the
design phase of the product from Polyganics BV.
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